Skip to Content

PhytoMedical's Anti-Cancer Compound Effective at Killing Brain Cancer Cells

PRINCETON, N.J.--(BUSINESS WIRE)--Jan. 3, 2008 - PhytoMedical Technologies, Inc. (OTCBB:PYTO) (FWB:ET6), today announced that research outcomes from ongoing in vitro studies of the Company's sponsored anti-cancer compounds have successfully demonstrated the ability to kill a strain of human brain cancer cells which is otherwise highly-resistant to currently available drugs.

Led by Dartmouth College researcher Dr. Gordon Gribble, researchers have determined that, one of several patented "bis-intercalator" anti-cancer compounds being developed by PhytoMedical has achieved a 50% or greater cancer cell kill rate at a minimum concentration in studies of the SF-295 strain of human glioblastoma (brain) cancer cells -- a significant outcome, given these brain cancer cells' drug-resistant nature.

"The outstanding results of this human cancer cell study is an extremely important step towards finding a potential solution for treating glioblastoma, an often fatal form of cancer," commented Greg Wujek, President, CEO of PhytoMedical Technologies, Inc. "The demonstrated cytotoxic effects of this unique patented compound on such a resistant strain of cancer has given us the confidence to move forward in our research and improve upon the concept of bis-intercalation and the promise it holds for the control of cancer."

In important in vitro experiments, researchers tested several variations of patented bis-intercalator compounds. These compounds have the unique capability to "intercalate" or insert their anti-cancer molecules inside DNA sites of specific cancer cells, thereby preventing the ability of the cancer cells to replicate and ultimately forcing their death.

"We are very happy," says Alla Kan Director of Dartmouth's Technology Transfer Office, "that we found a good partner to help us bring these powerful new drugs claimed in Dartmouth College issued patent #6,187,787 to the patient as this is an ultimate goal of our office, to utilize research taking place in our laboratories for the public good."

Among several compounds tested in vitro against an often fatal strain of human glioblastoma (brain) cells, researchers have identified a high performance compound which requires the least concentration in order to achieve a 50% or greater cancer cell kill rate. This strong activity against glioblastoma cancer cells is a significant achievement given these cells' strong resistance to currently available anticancer drugs such as Lomustine, Carmustine, Nitrosourea, Hydroxyurea, and Procarbazine.

PhytoMedical's Cancer Research: Killing Cancer's DNA

PhytoMedical is developing a novel class of patented anti-cancer agents that have a 'cytotoxic' or poisonous affinity for cancer cells and are designed to bind more tightly to cancer cell DNA than many conventional anticancer drugs by a process called bis-intercalation or "double binding," much like a molecular staple. Because the DNA is the blueprint of life for the cancer cell, such binding stops the replication of the DNA, which prevents the growth of the cancer cell and it dies.

DNA is present in the nucleus of every cell of all living organisms, which are constantly dividing through a process in which the DNA in the nucleus of the original cell replicates itself to be present in the nuclei of the two new ("daughter") cells. If this replication cannot occur, the cell will die and the organism will eventually stop growing and die. Cancer is characterized by the development of abnormal cells that divide uncontrollably and have the ability to infiltrate and destroy normal body tissue.

At present, anticancer molecules designed to block the replication of DNA do so through "intercalation," a mechanism in which the drug inserts itself between one set of adjacent base pairs of the DNA. PhytoMedical believes a more effective anticancer strategy is to design molecules ("bis-intercalators") that can intercalate simultaneously at two DNA sites, thus further increasing the binding between the drug and the DNA of specific cancer cells in order to stop their replication and ultimately resulting in the death of the cancer cell.

About PhytoMedical Technologies, Inc.

PhytoMedical Technologies, Inc. (OTCBB:PYTO; Frankfurt Stock Exchange:ET6), together with its wholly owned subsidiaries, is a pharmaceutical company focused on research, development and commercialization of pharmaceutical products.

For additional information, please visit

To receive future press releases via email, please visit

To view the full HTML text of this release, please visit:

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company's products, technical problems with the Company's research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our on going research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and /or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that PhytoMedical will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at The Company undertakes no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


PhytoMedical Technologies, Inc.
Mr. Greg Wujek, President & CEO
Phone: 800-611-3388

Posted: January 2008